We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
-4.41%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.13B
AUM Growth
-$213M
Cap. Flow
-$89.6M
Cap. Flow %
-7.9%
Top 10 Hldgs %
36.51%
Holding
116
New
25
Increased
32
Reduced
25
Closed
24

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$43.3M
2
TERN
Terns Pharmaceuticals
TERN
+$30M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$23.4M
4
TXG icon
10x Genomics
TXG
+$18.8M
5
ELVN icon
Enliven Therapeutics
ELVN
+$16.2M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$44.7M
2
UTHR icon
United Therapeutics
UTHR
+$31.3M
3
HCA icon
HCA Healthcare
HCA
+$17.2M
4
BIIB icon
Biogen
BIIB
+$15.7M
5
WGS icon
GeneDx Holdings
WGS
+$13.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.73%
2 Consumer Staples 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CVRX icon
51
CVRx
CVRX
$146M
$7.04M 0.62%
587,098
+538,598
+1,111% +$6.2M
INSM icon
52
Insmed
INSM
$21.3B
$6.87M 0.61%
102,472
-147,528
-59% -$5.72M
HIMS icon
53
Hims & Hers Health
HIMS
$7.13B
$6.72M 0.59%
+333,000
New +$5.54M
THTX
54
DELISTED
Theratechnologies
THTX
$6.72M 0.59%
4,801,376
– –
IMVT icon
55
Immunovant
IMVT
$7.91B
$6.65M 0.59%
251,900
-12,750
-5% -$363K
ADPT icon
56
Adaptive Biotechnologies
ADPT
$3.68B
$6.23M 0.55%
+1,720,000
New +$5.46M
APLT
57
DELISTED
Applied Therapeutics
APLT
$5.93M 0.52%
1,269,714
-295,202
-19% -$1.4M
GMED icon
58
Globus Medical
GMED
$11.1B
$5.89M 0.52%
+86,000
New +$5.14M
JAZZ icon
59
Jazz Pharmaceuticals
JAZZ
$15.8B
$5.76M 0.51%
+53,935
New +$5.93M
BCAB icon
60
BioAtla
BCAB
$5.41M
$5.34M 0.47%
78,026
-3,278
-4% -$390K
ERAS icon
61
Erasca
ERAS
$6.19B
$5.1M 0.45%
+2,162,162
New +$4.67M
VSTM icon
62
Verastem
VSTM
$500M
$4.95M 0.44%
1,661,297
+120,663
+8% +$995K
MREO
63
Mereo BioPharma
MREO
$50.4M
$4.49M 0.4%
1,246,953
-1,370,000
-52% -$4.44M
IRMD icon
64
iRadimed
IRMD
$1.17B
$4.48M 0.4%
102,067
-259,563
-72% -$11M
VRDN icon
65
Viridian Therapeutics
VRDN
$2.13B
$4.42M 0.39%
340,000
– –
EXAS
66
DELISTED
Exact Sciences
EXAS
$3.87M 0.34%
+91,611
New +$5.04M
PODD icon
67
Insulet
PODD
$11.8B
$3.79M 0.33%
+18,800
New +$3.39M
KNSA icon
68
Kiniksa Pharmaceuticals
KNSA
$5.73B
$3.73M 0.33%
+200,000
New +$3.75M
NSPR icon
69
InspireMD
NSPR
$31.9M
$3.44M 0.3%
1,378,128
– –
CALC icon
70
CalciMedica
CALC
$11.9M
$3.1M 0.27%
783,904
– –
SKIN icon
71
SkinHealth Systems
SKIN
$90.6M
$3.08M 0.27%
1,604,718
+1,434,718
+844% +$4.04M
SNY icon
72
Sanofi
SNY
$103B
$3.03M 0.27%
+62,500
New +$3.01M
FATE icon
73
Fate Therapeutics
FATE
$291M
$2.85M 0.25%
870,000
– –
XFOR icon
74
X4 Pharmaceuticals
XFOR
$386M
$2.35M 0.21%
135,033
-17,631
-12% -$577K
OLMA icon
75
Olema Pharmaceuticals
OLMA
$985M
$2.34M 0.21%
216,500
-441,500
-67% -$4.79M
1 2
3
4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Soleus Capital Management held 116 positions worth $1.13B, down 16% from $1.35B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Soleus Capital Management withdrew a net $89.6M in Q2 2024, closing 24 positions and reducing 25 holdings. Its most notable exit was HCA Healthcare, an estimated $17.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 84% a quarter earlier, followed by Consumer Staples.

Against the trend, Soleus Capital Management opened a new position in Terns Pharmaceuticals worth $33.7M.

  • Soleus Capital Management's largest Q2 2024 buy was Terns Pharmaceuticals: 4,947,738 shares worth $33.7M.
  • Soleus Capital Management added most to Iovance Biotherapeutics in Q2 2024, an estimated $43.3M increase.
  • Soleus Capital Management's biggest Q2 2024 reduction was Teva Pharmaceuticals, cutting an estimated $44.7M.
  • Soleus Capital Management fully exited HCA Healthcare in Q2 2024, selling an estimated $17.2M.
  • Soleus Capital Management's ten largest holdings make up 37% of its $1.13B portfolio in Q2 2024.
  • Soleus Capital Management opened 25 new positions and closed 24 in Q2 2024.
  • Soleus Capital Management's portfolio value fell 16% quarter-over-quarter to $1.13B.

Based on Soleus Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.